Literature DB >> 17716987

FDG-PET in T-cell and NK-cell neoplasms.

S Kako1, K Izutsu, Y Ota, Y Minatani, M Sugaya, T Momose, K Ohtomo, Y Kanda, S Chiba, T Motokura, M Kurokawa.   

Abstract

BACKGROUND: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma. The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms. PATIENTS AND METHODS: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification. Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).
RESULTS: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients. The positive rate was equally high in most histological subtypes except for cutaneous lymphomas: PTCLu 91%, ENKL 100%, C-ALCL 60%, AILT 100%. All the patients without an FDG-avid lesion had lesions restricted to skin. Among patients who had cutaneous lesions, only 50% had FDG-avid cutaneous lesions, all of which were tumorous. The positive rate of FDG-PET for bone marrow involvement was only 20%.
CONCLUSION: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716987     DOI: 10.1093/annonc/mdm265

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

1.  Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography.

Authors:  Dan Shao; Shu-Xia Wang; Chang-Hong Liang; Qiang Gao
Journal:  J Nucl Cardiol       Date:  2011-06-08       Impact factor: 5.952

2.  Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.

Authors:  Cinzia Pellegrini; Lisa Argnani; Alessandro Broccoli; Vittorio Stefoni; Enrico Derenzini; Letizia Gandolfi; Beatrice Casadei; Roberto Maglie; Stefano Pileri; Pier Luigi Zinzani
Journal:  Oncologist       Date:  2014-05-28

3.  FDG-PET scans in patients with lymphoma.

Authors:  Rebecca L Elstrom; John P Leonard
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

4.  Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with 18F-FDG PET/CT.

Authors:  William Makis; Anthony Ciarallo; Beatrice Wang; Milene Gonzalez-Verdecia; Stephan Probst
Journal:  Nucl Med Mol Imaging       Date:  2016-12-19

5.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

6.  PET in T-Cell Lymphoma.

Authors:  Pier Luigi Zinzani
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

7.  Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Bing Bai; Hui-Qiang Huang; Qi-Chun Cai; Wei Fan; Xiao-Xiao Wang; Xu Zhang; Ze-Xiao Lin; Yan Gao; Yun-Fei Xia; Ying Guo; Qing-Qing Cai; Wen-Qi Jiang; Tong-Yu Lin
Journal:  Med Oncol       Date:  2013-01-18       Impact factor: 3.064

Review 8.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

Review 9.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

10.  18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

Authors:  Carla Casulo; Heiko Schöder; John Feeney; Remy Lim; Jocelyn Maragulia; Andrew D Zelenetz; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2013-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.